Literature DB >> 12433228

Reduced tolerance of simulated altitude (4200 m) in young men with borderline hypertension.

C Ledderhos1, H Pongratz, J Exner, A Gens, D Roloff, A Honig.   

Abstract

BACKGROUND: Primary hypertensives who are acutely exposed to hypoxic hypoxia show an enhanced reactivity of arterial chemoreceptors as well as an exaggerated response of the sympathetic nervous system. Since these phenomena could influence their ability to tolerate sustained hypoxic hypoxia, this study was performed to determine whether persons predisposed to hypertension have a normal tolerance of simulated high altitude.
METHODS: Subjects were 18 young men with a family history of hypertension (sons of hypertensives, SOHT) whose BP values were in the upper normal or borderline hypertensive range. Controls were 15 young men without parental hypertension (sons of normotensives, SONT) who had normal BP values. Each subject underwent both a control and an altitude experiment. The latter consisted of an 8-h exposure to hypobaric hypoxia (equivalent to 4200 m) while resting supine in an altitude chamber. Fluids were administered by mouth and by intravenous line to produce sustained diuresis. Variables measured included heart rate, BP, respiratory rate, O2 saturation, urine flow rate, and sodium excretion.
RESULTS: All subjects tolerated the control experiment and all SONT also completed altitude exposure. However, 8 of 18 SOHT developed antidiuresis and had to leave the chamber early due to symptoms of mild acute mountain sickness. Compared with SONT, SOHT exhibited more stable cardiorespiratory parameters at altitude.
CONCLUSIONS: The data support the hypothesis that borderline hypertensives have stronger cardiorespiratory responses to altitude than controls, a response that is compatible with higher excitability of their arterial chemoreceptors. However, their altitude tolerance is reduced even at rest, probably because of the renal effects of an exaggerated response in the sympathetic nervous system.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12433228

Source DB:  PubMed          Journal:  Aviat Space Environ Med        ISSN: 0095-6562


  7 in total

1.  Preacclimatization in simulated altitudes.

Authors:  M Burtscher; E Brandstätter; H Gatterer
Journal:  Sleep Breath       Date:  2008-05       Impact factor: 2.816

Review 2.  [Arterial hypertension due to altitude].

Authors:  Wolfgang Domej; Michael Trapp; Eva Maria Miggitsch; Tiziana Krakher; Rita Riedlbauer; Peter Roher; Günther Schwaberger
Journal:  Wien Med Wochenschr       Date:  2008

3.  Hypoxia stress test reveals exaggerated cardiovascular effects in hypertensive rats after exposure to the air pollutant acrolein.

Authors:  Christina M Perez; Allen D Ledbetter; Mehdi S Hazari; Najwa Haykal-Coates; Alex P Carll; Darrell W Winsett; Daniel L Costa; Aimen K Farraj
Journal:  Toxicol Sci       Date:  2013-01-18       Impact factor: 4.849

4.  Hypertension and Acute Mountain Sickness in Himalayan Trekkers in Nepal: An Observational Cohort Study.

Authors:  Charles B Duke; T Douglas Sallade; Jennifer Starling; Sushil Pant; Alison Sheets; Matthew K McElwee; David S Young; Richard Andrew Taylor; Linda E Keyes
Journal:  Wilderness Environ Med       Date:  2020-03-21       Impact factor: 1.518

5.  Correlation between blood pressure changes and AMS, sleeping quality and exercise upon high-altitude exposure in young Chinese men.

Authors:  Yang Liu; Ji-Hang Zhang; Xu-Bin Gao; Xiao-Jing Wu; Jie Yu; Jian-Fei Chen; Shi-Zhu Bian; Xiao-Han Ding; Lan Huang
Journal:  Mil Med Res       Date:  2014-08-26

6.  Heart rate and blood pressure responses during hypoxic cycles of a 3-week intermittent hypoxia breathing program in patients at risk for or with mild COPD.

Authors:  Martin Faulhaber; Hannes Gatterer; Thomas Haider; Tobias Linser; Nikolaus Netzer; Martin Burtscher
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2015-02-11

Review 7.  Body Composition and Body Weight Changes at Different Altitude Levels: A Systematic Review and Meta-Analysis.

Authors:  Tobias Dünnwald; Hannes Gatterer; Martin Faulhaber; Marjan Arvandi; Wolfgang Schobersberger
Journal:  Front Physiol       Date:  2019-04-16       Impact factor: 4.566

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.